BlossomHill Therapeutics (BLSM) elevated its outlook on Tuesday after presenting Phase I data for BH-30643, its lead EGFR inhibitor targeting C797S-resistant mutations in non-small cell lung cancer (NSCLC). The company reported a 45% objective response rate in its efficacy-evaluable cohort of 40 patients, with an 88% disease control rate, marking a significant advancement in addressing a decade-old clinical challenge. The drug demonstrated tenfold greater potency than osimertinib (Tagrisso), a key differentiator in a competitive oncology landscape.
The data, presented at the H.C. Wainwright 28th Annual Global Investment Conference, also highlighted durability in the treatment, with 63 patients remaining on study at the median follow-up of 6.9 months. Expansion cohorts tested doses of 40 mg, 50 mg, and 60 mg twice daily, showing a 9% dose-reduction rate and a 3% treatment discontinuation rate, with manageable safety profiles including grade 1/2 adverse events like bilirubin elevation and rash. The company’s balance sheet remains strong, with a current ratio of 7.4 and a market capitalization of $666 million, reflecting robust financial health.
The positive trajectory aligns with BlossomHill’s upcoming milestones: an end-of-Phase I FDA meeting for BH-30643 in Q4 2026, followed by pivotal Phase II design discussions for the C797S-resistant population. In 2027, the company plans to submit an Investigational New Drug (IND) application for BH-501284, its pan-KRAS inhibitor, and expects additional durability data for BH-30643 in the first half of the year. The company’s IPO is scheduled for August 2026, with analyst price targets ranging from $28 to $36, reflecting a 36% return over the past six months and a stock price of $22.40 as of the presentation.
The data underscored BlossomHill’s focus on addressing treatment gaps, particularly for patients with C797S-resistant NSCLC, a population historically underrepresented in clinical trials. The company’s pipeline also includes a CLK inhibitor in dose escalation studies, both as monotherapy and in combination with venetoclax, as well as preclinical comparisons with other KRAS-targeting therapies at the upcoming American Association for Cancer Research (AACR) meeting.
Analysts and investors highlighted the potential for BH-30643 to redefine standard-of-care options, particularly in the context of rising resistance to first-line therapies. The company’s CEO, J. Jean Cui, emphasized the importance of durability and efficacy improvements for late-stage developers, positioning BlossomHill as a candidate to meet those expectations.
With an IPO looming and a robust pipeline, BlossomHill Therapeutics is positioning itself as a key player in the evolving oncology drug market, where precision-targeted therapies are increasingly prioritized over broad-spectrum approaches.
